Different formulations of botulinum toxin type A have different migration characteristics: A double-blind, randomized study

Journal of Cosmetic Dermatology

Volumn 7, Issue 1, 2008, Pages 50-54

  Cliff, Sandeep H ^a   Judodihardjo, Harryono ^b   Eltringham, Elizabeth ^c  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Cellite Clinic Ltd   (United Kingdom)

^c SIMBEC RESEARCH LTD   (United Kingdom)

Author keywords

Adverse effect; Anhidrosis; Botox; Botulinum toxin; Dysport; Migration

Indexed keywords

BOTULINUM TOXIN A; SODIUM CHLORIDE;

ADULT; ANHIDROSIS; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RESPONSE; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHOTOGRAPHY; PRIORITY JOURNAL; SKIN TIGHTNESS; SWEAT TEST; SWEATING;

ADULT; ANALYSIS OF VARIANCE; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; FOREHEAD; HUMANS; HYPOHIDROSIS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRADERMAL; IODINE; MALE; NEUROMUSCULAR AGENTS; PILOT PROJECTS; STARCH;

EID: 38949200265     PISSN: 14732130     EISSN: 14732165     Source Type: Journal    
DOI: 10.1111/j.1473-2165.2008.00361.x     Document Type: Article

References (23)

1. Botox ® Prescribing Information. Accessed June 6, 2006, from http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid=112.
2. Dysport ® Prescribing Information. Accessed June 6, 2006, from http://emc.medicines.org.uk/emc/assets/c/html/ displaydoc.asp?documentid=870.
3. Smuts JA, de Boulle K, van Coller R, Barnard PWA. An electrophysiological study to demonstrate in vivo differences between two types of botulinum toxin type A (BOTOX® and DYSPORT®). Poster presented at the 8th International Congress of Parkinson's Disease and Movement Disorder, June 13-17, 2004, Rome, Italy.
4. Lowe P, Patnaik R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. J Am Acad Dermatol 2006; 55: 975-80. Epub 2006 Oct 6.
5. Trindade de Almeida AR, Marques E, de Almeida J, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (Suppl. 1): S37-43.
6. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994; 9: 31-9.
7. Tugnoli V, Eleopra R, Montecucco C, De Grandis D. The therapeutic use of botulinum toxin. Expert Opin Invest Drugs 1997; 6: 1383-94.
8. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140: 1351-4.
9. Aoki R, Francis J, Reynolds H, Leumer D. Comparison of the therapeutic windows of different botulinum neurotoxin preparations in an animal model. Neurology 2003; 60 (5 Suppl. 1): A212-3 [P03.088].
10. Lew H, Yun YS, Lee SY, Kim SJ. Effect of botulinum toxin A on facial wrinkle lines in Koreans. Ophthalmologica 2002; 216: 50-4.
11. Nügens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 1997; 235: 197-9.
12. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62.
13. Dodel RC, Kirchner A, Koehne-Volland R et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997; 12: 695-706.
14. Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotox Res 2006; 9: 173-7.
15. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport® vs. Botox® in primary palmar hyperhidrosis. Br J Dermatol 2003; 149: 1041-5.
16. Roche N, Schnitzler A, Genêt F et al. Uncontrolled migration outside the targeted muscle associated with adverse effect of botulinum toxin type A distant from the injection site: a preliminary analysis. Poster presented at the 67th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, November 11, 2006: Honolulu, HI.
17. Talarico-Filho S, Mendonça do Nascimento M, Sperandeo de Macedo F, de Sanctis Pecora C. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S44-50.
18. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin - from laboratory to bedside. Neurotox Res 2006; 9: 133-40.
19. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 2001; 39: 1815-20.
20. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2007; 13 (Suppl. 4): 10-9.
21. Hambleton P, Capel B, Bailey N et al. Production, purification and toxoiding of Clostridium botulinum type A toxin. In: GE Jr Lewis, ed. Biomedical Aspects of Botulism. New York: Academic Press; 1981: 247-60.
22. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 1992; 239: 16-20.
23. Ward AB. Migration properties of two different botulinum toxin type A formulations in the lower-middle back. Poster presented at the 67th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation, November 9-12, 2006, Honolulu, Hawaii, USA.